Male Health Drug Development Pipeline Review, 2017

Friday, October 13, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Oct. 12, 2017 /PRNewswire/ -- Male Health Drug Development Pipeline Review, 2017

Summary

Male

hypogonadism is characterized by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). There are a total of
23 products in development for this indication, by 19 companies and one academic institution. Key companies operating in this pipeline space include Lipocine, M et P Pharma, Repros Therapeutics and TesoRx Pharma.Read the full report: https://www.reportlinker.com/p05142592Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient to permit satisfactory intercourse. There are a total of 36 products in development for this indication, by 31 companies and two academic institutions. Key companies operating in this pipeline space include Mitsubishi Tanabe Pharma, Futura Medical, Monosol Rx and NAL Pharmaceuticals.Finally, Benign prostatic hyperplasia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 29 products in development for this indication, by 26 companies and four academic institutions. Key companies operating in this pipeline space include Chong Kun Dang Pharmaceutical, Nymox Pharmaceutical and Yungjin Pharm.The most common target for male hypogonadism is the androgen receptor, while phosphodiesterase 5 targets dominate the erectile dysfunction pipeline. Targets for the treatment of benign prostatic hyperplasia are more diverse with a strong presence of both androgen receptor and phosphodiesterase targets.The report, "Male Health Drug Development Pipeline Review, 2017" provides an overview of the male health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia and features dormant and discontinued projects.Scope- Which companies are the most active within the pipeline for male health therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of male health?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05142592 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com  __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/male-health-drug-development-pipeline-review-2017-300536106.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook